← Back to Search

Behavioral Intervention

Mailed FIT Outreach 2022

N/A
Waitlist Available
Led By Shivan Mehta, MD
Research Sponsored by Abramson Cancer Center at Penn Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test different ways to increase the number of people who get screened for colorectal cancer, including mailing them a FIT kit and sending reminders.

Eligible Conditions
  • Colorectal Cancer
  • Colon Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
FIT Completion
Secondary study objectives
Colorectal Cancer (CRC) Screening Completion (Any)
FIT Positive Follow-up Completion
FIT Positive Follow-up Scheduling

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

8Treatment groups
Experimental Treatment
Group I: Arm 8: Standard Mail + No Text + No ReminderExperimental Treatment3 Interventions
Standard Mail + No Text + No Reminder
Group II: Arm 7: Standard Mail + No Text + ReminderExperimental Treatment3 Interventions
Group III: Arm 6: Standard Mail + Text + No ReminderExperimental Treatment3 Interventions
Standard Mail + Text + No Reminder
Group IV: Arm 5: Standard Mail + Text + ReminderExperimental Treatment3 Interventions
Standard Mail + Text + Reminder
Group V: Arm 4: Box + No Text + No ReminderExperimental Treatment3 Interventions
Box + No Text + No Reminder
Group VI: Arm 3: Box + No Text + ReminderExperimental Treatment3 Interventions
Box + No Text + Reminder
Group VII: Arm 2: Box + Text + No ReminderExperimental Treatment3 Interventions
Box + Text + No Reminder
Group VIII: Arm 1: Box + Text + ReminderExperimental Treatment3 Interventions
Box + Text + Reminder
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Differentiated Box
2022
N/A
~5460
Standard Mail
2022
N/A
~5460
Text
2022
N/A
~5500
No Text
2022
N/A
~5460
Reminder
2023
Completed Early Phase 1
~311310
No Reminder
2022
N/A
~5460

Find a Location

Who is running the clinical trial?

Abramson Cancer Center at Penn MedicineLead Sponsor
418 Previous Clinical Trials
459,392 Total Patients Enrolled
Abramson Cancer Center of the University of PennsylvaniaLead Sponsor
359 Previous Clinical Trials
103,025 Total Patients Enrolled
Shivan Mehta, MDPrincipal InvestigatorUniversity of Pennsylvania
15 Previous Clinical Trials
72,207 Total Patients Enrolled
~1560 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top